Lupin launches Molnupiravir in India

12 Jan 2022 , 01:34 AM

Lupin announced the launch of Molnupiravir in India under the brand name Molnulup This drug has been given emergency use authorization by the Drug Controller General of India DCGI for treatment of adult patients with Covid19 with SpO2 > 93Percentage and the ones who have a high risk of progression of the disease including hospitalization Internationally Molnupiravir is an oral antiviral that has been approved by the UK Medicines and Healthcare products Regulatory Agency MHRA and the US Food and Drug Administration FDA for the treatment of mild-to-moderate cases of COVID-19 in adults Administered orally Molnupiravir inhibits the replication of SARS-CoV-2 the causative agent of COVID19 Pre-clinical and clinical data have shown Molnupiravir to be effective against the most common SARSCoV-2 variants including Gamma Delta and Mu variants Molnupiravir should be initiated as soon as possible after a diagnosis of COVID-19 and within five days of onset of symptoms Clinical data points suggest that Molnupiravir may be a gamechanger for the most vulnerable and immunosuppressed patients This would include factors such as obesity older age >60 years diabetes or heart disease